Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Ultragenyx Pharmaceutical ( (RARE) ).
On July 31, 2025, Ultragenyx Pharmaceutical announced that the Phase 3 Aspire study for GTX-102, a treatment for Angelman Syndrome, is fully enrolled with 129 participants. The study, which began in December 2024, involves a 48-week trial comparing GTX-102 treatment to a sham comparator group, with primary and secondary endpoints focusing on cognitive improvements and multi-domain responses. Completion is expected in the second half of 2026, with plans to provide topline data and progress to regulatory submission.
The most recent analyst rating on (RARE) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Ultragenyx Pharmaceutical stock, see the RARE Stock Forecast page.
Spark’s Take on RARE Stock
According to Spark, TipRanks’ AI Analyst, RARE is a Neutral.
Ultragenyx Pharmaceutical’s overall stock score is driven by its challenging financial performance, reflected in poor profitability and cash flow, alongside bearish technical indicators and an unattractive valuation. The earnings call provided some optimism with strong revenue growth and advancement in clinical trials, but significant losses and cash usage remain concerns. Corporate events offer potential future growth catalysts, though recent regulatory setbacks highlight ongoing risks.
To see Spark’s full report on RARE stock, click here.
More about Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. operates in the biopharmaceutical industry, focusing on developing novel products for the treatment of rare and ultra-rare genetic diseases.
Average Trading Volume: 1,759,952
Technical Sentiment Signal: Sell
Current Market Cap: $2.62B
See more insights into RARE stock on TipRanks’ Stock Analysis page.